A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-08

AUTHORS

B. J. Eigl, S. North, E. Winquist, D. Finch, L. Wood, S. S. Sridhar, J. Powers, J. Good, M. Sharma, J. A. Squire, J. Bazov, T. Jamaspishvili, M. E. Cox, P. A. Bradbury, E. A. Eisenhauer, K. N. Chi

ABSTRACT

BACKGROUND: SB939 is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDACs). These three HDAC classes are highly expressed in castration resistant prostate cancer (CRPC) and associated with poor clinical outcomes. We designed a phase II study of SB939 in men with metastatic CRPC. METHODS: Patients received SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle. Primary endpoints were PSA response rate (RR) and progression-free survival (PFS). Secondary endpoints included objective response rate and duration; overall survival; circulating tumor cell (CTC) enumeration and safety. Exploratory correlative studies of the TMPRSS2-ERG fusion and PTEN biomarkers were also performed. RESULTS: Thirty-two patients were enrolled of whom 88 % had received no prior chemotherapy. The median number of SB939 cycles administered was three (range 1-8). Adverse events were generally grade 1-2, with five pts experiencing one or more grade three event. One patient died due to myocardial infarction. A confirmed PSA response was noted in two pts (6 %), lasting 3.0 and 21.6 months. In patients with measurable disease there were no objective responses. Six patients had stable disease lasting 1.7 to 8.0 months. CTC response (from ≥5 at baseline to <5 at 6 or 12 weeks) occurred in 9/14 evaluable patients (64 %). CONCLUSION: Although SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC. More... »

PAGES

969-976

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4

DOI

http://dx.doi.org/10.1007/s10637-015-0252-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016709489

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25983041


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histone Deacetylase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kallikreins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplastic Cells, Circulating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "PTEN Phosphohydrolase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms, Castration-Resistant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serine Endopeptidases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trans-Activators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcriptional Regulator ERG", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eigl", 
        "givenName": "B. J.", 
        "id": "sg:person.0726367435.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726367435.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alberta", 
          "id": "https://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Cross Cancer Institute, Edmonton, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "North", 
        "givenName": "S.", 
        "id": "sg:person.01151470300.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London Health Sciences Centre", 
          "id": "https://www.grid.ac/institutes/grid.412745.1", 
          "name": [
            "London Health Sciences Centre, London, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winquist", 
        "givenName": "E.", 
        "id": "sg:person.01031740163.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency, Kelowna, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finch", 
        "givenName": "D.", 
        "id": "sg:person.01123665025.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123665025.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Elizabeth II Health Sciences Centre", 
          "id": "https://www.grid.ac/institutes/grid.413292.f", 
          "name": [
            "QEII Health Sciences Centre, Halifax, NS, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "L.", 
        "id": "sg:person.012366031317.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012366031317.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "Princess Margaret Cancer Centre, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sridhar", 
        "givenName": "S. S.", 
        "id": "sg:person.01204166657.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204166657.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powers", 
        "givenName": "J.", 
        "id": "sg:person.0764776730.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764776730.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "Queens University, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Good", 
        "givenName": "J.", 
        "id": "sg:person.0770570454.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770570454.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vancouver General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412541.7", 
          "name": [
            "Vancouver Prostate Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "M.", 
        "id": "sg:person.0734267142.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734267142.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "Queens University, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Squire", 
        "givenName": "J. A.", 
        "id": "sg:person.01200416665.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200416665.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vancouver General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412541.7", 
          "name": [
            "Vancouver Prostate Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bazov", 
        "givenName": "J.", 
        "id": "sg:person.01162310346.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162310346.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "Queens University, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jamaspishvili", 
        "givenName": "T.", 
        "id": "sg:person.01217554331.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217554331.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vancouver General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412541.7", 
          "name": [
            "Vancouver Prostate Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cox", 
        "givenName": "M. E.", 
        "id": "sg:person.0625033457.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625033457.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bradbury", 
        "givenName": "P. A.", 
        "id": "sg:person.010072170137.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010072170137.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eisenhauer", 
        "givenName": "E. A.", 
        "id": "sg:person.0610741743.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610741743.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "K. N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nprot.2008.73", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005355981", 
          "https://doi.org/10.1038/nprot.2008.73"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-3093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006258831"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/gcc.20939", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006589958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-09-0689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008255520"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1096/fj.12-222893", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010089332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-1986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012813855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5772/27799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014327053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2224-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017758793", 
          "https://doi.org/10.1007/s00280-013-2224-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020189480", 
          "https://doi.org/10.1038/sj.bjc.6605293"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp270", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020236226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.1314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020702285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021371367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021855880", 
          "https://doi.org/10.1007/s00280-010-1289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021855880", 
          "https://doi.org/10.1007/s00280-010-1289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng0509-509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022216670", 
          "https://doi.org/10.1038/ng0509-509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng0509-509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022216670", 
          "https://doi.org/10.1038/ng0509-509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2008.96", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023686924", 
          "https://doi.org/10.1038/modpathol.2008.96"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.4487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031178629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034222572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034680444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1715", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035724264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036295056", 
          "https://doi.org/10.1038/bjc.2011.13"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040372140"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/bse0400041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044072468"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/81671", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044273521", 
          "https://doi.org/10.1038/81671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/81671", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044273521", 
          "https://doi.org/10.1038/81671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0b013e31821e8761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044599683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0b013e31821e8761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044599683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.08.6165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047140065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-2216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048751420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052387252", 
          "https://doi.org/10.1038/sj.bjc.6604199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm2003552", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055952282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm2003552", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055952282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/epi.3.6.7273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072302870"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-08", 
    "datePublishedReg": "2015-08-01", 
    "description": "BACKGROUND: SB939 is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDACs). These three HDAC classes are highly expressed in castration resistant prostate cancer (CRPC) and associated with poor clinical outcomes. We designed a phase II study of SB939 in men with metastatic CRPC.\nMETHODS: Patients received SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle. Primary endpoints were PSA response rate (RR) and progression-free survival (PFS). Secondary endpoints included objective response rate and duration; overall survival; circulating tumor cell (CTC) enumeration and safety. Exploratory correlative studies of the TMPRSS2-ERG fusion and PTEN biomarkers were also performed.\nRESULTS: Thirty-two patients were enrolled of whom 88 % had received no prior chemotherapy. The median number of SB939 cycles administered was three (range 1-8). Adverse events were generally grade 1-2, with five pts experiencing one or more grade three event. One patient died due to myocardial infarction. A confirmed PSA response was noted in two pts (6 %), lasting 3.0 and 21.6 months. In patients with measurable disease there were no objective responses. Six patients had stable disease lasting 1.7 to 8.0 months. CTC response (from \u22655 at baseline to <5 at 6 or 12 weeks) occurred in 9/14 evaluable patients (64 %).\nCONCLUSION: Although SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-015-0252-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "name": "A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195", 
    "pagination": "969-976", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4f9d24ca9916cb008302f428ac7e70e78bced0eb6d4f4f3ea2d6513e4e7dc62c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25983041"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-015-0252-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016709489"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-015-0252-4", 
      "https://app.dimensions.ai/details/publication/pub.1016709489"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89819_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-015-0252-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-015-0252-4'


 

This table displays all metadata directly associated to this object as RDF triples.

364 TRIPLES      21 PREDICATES      77 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-015-0252-4 schema:about N00cf1860f07d46d0ac0d77ff372b1a10
2 N0b7d30ac38454a2886938772627a8f56
3 N0fcb064e61f34c25b352cc7a5c61b8c5
4 N107925db13aa4185a1492de91d32e643
5 N16037e5dfac3421fbd550f8f58cb0d39
6 N311d93ee696442e49a3bb1e110ec3800
7 N35cdc08762a84fe3867e4577bc32b18c
8 N3ad5c2e5afda46a39dde7155a943a3e5
9 N3bbd7c8946b549c8b15ec188c03162e6
10 N6f2c55c4ff21445085e848234a024c28
11 N80977de314df4f67b410a4e2ff1d58e8
12 N8dfab5dfa9474a5c8a4dd6d84cdcbd48
13 Nab9591e362034f4aa264b18bcd7a2e48
14 Nbd4cf4e0c3c54307a058f27d4344f766
15 Nbe7f03055c014e6d995819d88a137686
16 Nd300f561f7b142fbb25f05d165844af2
17 Ne555848f52a448b693f61739785c3773
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N82063d44dc9d4dbfb1d2a89feae18755
21 schema:citation sg:pub.10.1007/s00280-010-1289-x
22 sg:pub.10.1007/s00280-013-2224-8
23 sg:pub.10.1038/81671
24 sg:pub.10.1038/bjc.2011.13
25 sg:pub.10.1038/modpathol.2008.96
26 sg:pub.10.1038/ng0509-509
27 sg:pub.10.1038/nprot.2008.73
28 sg:pub.10.1038/sj.bjc.6604199
29 sg:pub.10.1038/sj.bjc.6605293
30 https://doi.org/10.1002/gcc.20939
31 https://doi.org/10.1016/0197-2456(89)90015-9
32 https://doi.org/10.1016/j.ejca.2008.10.026
33 https://doi.org/10.1021/jm2003552
34 https://doi.org/10.1042/bse0400041
35 https://doi.org/10.1093/annonc/mdp270
36 https://doi.org/10.1093/annonc/mdq784
37 https://doi.org/10.1096/fj.12-222893
38 https://doi.org/10.1097/pas.0b013e31821e8761
39 https://doi.org/10.1158/0008-5472.can-06-1986
40 https://doi.org/10.1158/0008-5472.can-08-2216
41 https://doi.org/10.1158/1078-0432.ccr-06-1715
42 https://doi.org/10.1158/1078-0432.ccr-06-3093
43 https://doi.org/10.1158/1078-0432.ccr-08-0872
44 https://doi.org/10.1158/1078-0432.ccr-11-1244
45 https://doi.org/10.1158/1535-7163.mct-06-0761
46 https://doi.org/10.1158/1535-7163.mct-09-0689
47 https://doi.org/10.1200/jco.2006.08.6165
48 https://doi.org/10.1200/jco.2007.12.4487
49 https://doi.org/10.18632/oncotarget.1314
50 https://doi.org/10.4161/epi.3.6.7273
51 https://doi.org/10.5772/27799
52 schema:datePublished 2015-08
53 schema:datePublishedReg 2015-08-01
54 schema:description BACKGROUND: SB939 is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDACs). These three HDAC classes are highly expressed in castration resistant prostate cancer (CRPC) and associated with poor clinical outcomes. We designed a phase II study of SB939 in men with metastatic CRPC. METHODS: Patients received SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle. Primary endpoints were PSA response rate (RR) and progression-free survival (PFS). Secondary endpoints included objective response rate and duration; overall survival; circulating tumor cell (CTC) enumeration and safety. Exploratory correlative studies of the TMPRSS2-ERG fusion and PTEN biomarkers were also performed. RESULTS: Thirty-two patients were enrolled of whom 88 % had received no prior chemotherapy. The median number of SB939 cycles administered was three (range 1-8). Adverse events were generally grade 1-2, with five pts experiencing one or more grade three event. One patient died due to myocardial infarction. A confirmed PSA response was noted in two pts (6 %), lasting 3.0 and 21.6 months. In patients with measurable disease there were no objective responses. Six patients had stable disease lasting 1.7 to 8.0 months. CTC response (from ≥5 at baseline to <5 at 6 or 12 weeks) occurred in 9/14 evaluable patients (64 %). CONCLUSION: Although SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC.
55 schema:genre research_article
56 schema:inLanguage en
57 schema:isAccessibleForFree false
58 schema:isPartOf N75910a0d809b4b75bde70e3a177ffd1e
59 Ne844f26ece454b909c37021462c7238b
60 sg:journal.1094201
61 schema:name A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
62 schema:pagination 969-976
63 schema:productId N122ecef1a8cf4d38827dafc9c2dc9224
64 N5180276b96b54c95b82c1a661c1e7bb5
65 N5a9d0c9f009746eda5b21ce4903d2137
66 Naa3bb092b50045a98e1c4a1c4bbdd87d
67 Ne4f23efed28f438d90f9124168bd1b93
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016709489
69 https://doi.org/10.1007/s10637-015-0252-4
70 schema:sdDatePublished 2019-04-11T10:01
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher N188619ffaa4e4802a03c2d9613713456
73 schema:url https://link.springer.com/10.1007%2Fs10637-015-0252-4
74 sgo:license sg:explorer/license/
75 sgo:sdDataset articles
76 rdf:type schema:ScholarlyArticle
77 N00cf1860f07d46d0ac0d77ff372b1a10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Aged
79 rdf:type schema:DefinedTerm
80 N0b7d30ac38454a2886938772627a8f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Kallikreins
82 rdf:type schema:DefinedTerm
83 N0d3b52b62f044635b07ba6867ad9855b rdf:first sg:person.01204166657.51
84 rdf:rest N71e0165419b84cf38611279dd9adb722
85 N0fcb064e61f34c25b352cc7a5c61b8c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name PTEN Phosphohydrolase
87 rdf:type schema:DefinedTerm
88 N107925db13aa4185a1492de91d32e643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Transcriptional Regulator ERG
90 rdf:type schema:DefinedTerm
91 N122ecef1a8cf4d38827dafc9c2dc9224 schema:name pubmed_id
92 schema:value 25983041
93 rdf:type schema:PropertyValue
94 N14cd863da16b411d91947ce8bb0853a3 rdf:first sg:person.01200416665.17
95 rdf:rest Ne1fd4aeb88b747738d22e93ec019c717
96 N14f391b73a8e4530a95ed5ce996fb783 rdf:first sg:person.0625033457.74
97 rdf:rest N65d942916e7c41d087ae7c6c29c64155
98 N16037e5dfac3421fbd550f8f58cb0d39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Trans-Activators
100 rdf:type schema:DefinedTerm
101 N188619ffaa4e4802a03c2d9613713456 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N239c861f342248fb9ee4ccb238de38d2 rdf:first sg:person.01142252161.65
104 rdf:rest rdf:nil
105 N311d93ee696442e49a3bb1e110ec3800 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Serine Endopeptidases
107 rdf:type schema:DefinedTerm
108 N35cdc08762a84fe3867e4577bc32b18c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Prostatic Neoplasms, Castration-Resistant
110 rdf:type schema:DefinedTerm
111 N3ad5c2e5afda46a39dde7155a943a3e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Neoplastic Cells, Circulating
113 rdf:type schema:DefinedTerm
114 N3bbd7c8946b549c8b15ec188c03162e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Humans
116 rdf:type schema:DefinedTerm
117 N5180276b96b54c95b82c1a661c1e7bb5 schema:name doi
118 schema:value 10.1007/s10637-015-0252-4
119 rdf:type schema:PropertyValue
120 N5a9d0c9f009746eda5b21ce4903d2137 schema:name dimensions_id
121 schema:value pub.1016709489
122 rdf:type schema:PropertyValue
123 N617f9ebbe6524c9ebbce41ddc4c1f421 rdf:first sg:person.01123665025.96
124 rdf:rest N8f04ef2646b8489ea1222f3152476001
125 N65d942916e7c41d087ae7c6c29c64155 rdf:first sg:person.010072170137.30
126 rdf:rest N6ee7358e328c41d69db7a9668125b7c9
127 N6ee7358e328c41d69db7a9668125b7c9 rdf:first sg:person.0610741743.91
128 rdf:rest N239c861f342248fb9ee4ccb238de38d2
129 N6f2c55c4ff21445085e848234a024c28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Antineoplastic Agents
131 rdf:type schema:DefinedTerm
132 N71e0165419b84cf38611279dd9adb722 rdf:first sg:person.0764776730.50
133 rdf:rest Nee88ba7a18914cfa8644368352a34a20
134 N75910a0d809b4b75bde70e3a177ffd1e schema:issueNumber 4
135 rdf:type schema:PublicationIssue
136 N80977de314df4f67b410a4e2ff1d58e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Histone Deacetylase Inhibitors
138 rdf:type schema:DefinedTerm
139 N82063d44dc9d4dbfb1d2a89feae18755 rdf:first sg:person.0726367435.98
140 rdf:rest Neba5d4b7b8c2443995ec89657816c7c8
141 N8a91021766824d6cae3e7e54648ffe99 rdf:first sg:person.01217554331.32
142 rdf:rest N14f391b73a8e4530a95ed5ce996fb783
143 N8dfab5dfa9474a5c8a4dd6d84cdcbd48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Prostate-Specific Antigen
145 rdf:type schema:DefinedTerm
146 N8f04ef2646b8489ea1222f3152476001 rdf:first sg:person.012366031317.20
147 rdf:rest N0d3b52b62f044635b07ba6867ad9855b
148 N93944bf195374561b3b208b20272920e rdf:first sg:person.01031740163.39
149 rdf:rest N617f9ebbe6524c9ebbce41ddc4c1f421
150 Naa3bb092b50045a98e1c4a1c4bbdd87d schema:name readcube_id
151 schema:value 4f9d24ca9916cb008302f428ac7e70e78bced0eb6d4f4f3ea2d6513e4e7dc62c
152 rdf:type schema:PropertyValue
153 Nab9591e362034f4aa264b18bcd7a2e48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Middle Aged
155 rdf:type schema:DefinedTerm
156 Nbd4cf4e0c3c54307a058f27d4344f766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged, 80 and over
158 rdf:type schema:DefinedTerm
159 Nbe7f03055c014e6d995819d88a137686 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Male
161 rdf:type schema:DefinedTerm
162 Nd17c704e7eda41b897bef1838a4dae7e rdf:first sg:person.0734267142.34
163 rdf:rest N14cd863da16b411d91947ce8bb0853a3
164 Nd300f561f7b142fbb25f05d165844af2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Disease-Free Survival
166 rdf:type schema:DefinedTerm
167 Ne1fd4aeb88b747738d22e93ec019c717 rdf:first sg:person.01162310346.28
168 rdf:rest N8a91021766824d6cae3e7e54648ffe99
169 Ne4f23efed28f438d90f9124168bd1b93 schema:name nlm_unique_id
170 schema:value 8309330
171 rdf:type schema:PropertyValue
172 Ne555848f52a448b693f61739785c3773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Benzimidazoles
174 rdf:type schema:DefinedTerm
175 Ne844f26ece454b909c37021462c7238b schema:volumeNumber 33
176 rdf:type schema:PublicationVolume
177 Neba5d4b7b8c2443995ec89657816c7c8 rdf:first sg:person.01151470300.91
178 rdf:rest N93944bf195374561b3b208b20272920e
179 Nee88ba7a18914cfa8644368352a34a20 rdf:first sg:person.0770570454.05
180 rdf:rest Nd17c704e7eda41b897bef1838a4dae7e
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1094201 schema:issn 0167-6997
188 1573-0646
189 schema:name Investigational New Drugs
190 rdf:type schema:Periodical
191 sg:person.010072170137.30 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
192 schema:familyName Bradbury
193 schema:givenName P. A.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010072170137.30
195 rdf:type schema:Person
196 sg:person.01031740163.39 schema:affiliation https://www.grid.ac/institutes/grid.412745.1
197 schema:familyName Winquist
198 schema:givenName E.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39
200 rdf:type schema:Person
201 sg:person.01123665025.96 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
202 schema:familyName Finch
203 schema:givenName D.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123665025.96
205 rdf:type schema:Person
206 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
207 schema:familyName Chi
208 schema:givenName K. N.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
210 rdf:type schema:Person
211 sg:person.01151470300.91 schema:affiliation https://www.grid.ac/institutes/grid.17089.37
212 schema:familyName North
213 schema:givenName S.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91
215 rdf:type schema:Person
216 sg:person.01162310346.28 schema:affiliation https://www.grid.ac/institutes/grid.412541.7
217 schema:familyName Bazov
218 schema:givenName J.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162310346.28
220 rdf:type schema:Person
221 sg:person.01200416665.17 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
222 schema:familyName Squire
223 schema:givenName J. A.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200416665.17
225 rdf:type schema:Person
226 sg:person.01204166657.51 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
227 schema:familyName Sridhar
228 schema:givenName S. S.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204166657.51
230 rdf:type schema:Person
231 sg:person.01217554331.32 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
232 schema:familyName Jamaspishvili
233 schema:givenName T.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217554331.32
235 rdf:type schema:Person
236 sg:person.012366031317.20 schema:affiliation https://www.grid.ac/institutes/grid.413292.f
237 schema:familyName Wood
238 schema:givenName L.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012366031317.20
240 rdf:type schema:Person
241 sg:person.0610741743.91 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
242 schema:familyName Eisenhauer
243 schema:givenName E. A.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610741743.91
245 rdf:type schema:Person
246 sg:person.0625033457.74 schema:affiliation https://www.grid.ac/institutes/grid.412541.7
247 schema:familyName Cox
248 schema:givenName M. E.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625033457.74
250 rdf:type schema:Person
251 sg:person.0726367435.98 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
252 schema:familyName Eigl
253 schema:givenName B. J.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726367435.98
255 rdf:type schema:Person
256 sg:person.0734267142.34 schema:affiliation https://www.grid.ac/institutes/grid.412541.7
257 schema:familyName Sharma
258 schema:givenName M.
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734267142.34
260 rdf:type schema:Person
261 sg:person.0764776730.50 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
262 schema:familyName Powers
263 schema:givenName J.
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764776730.50
265 rdf:type schema:Person
266 sg:person.0770570454.05 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
267 schema:familyName Good
268 schema:givenName J.
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770570454.05
270 rdf:type schema:Person
271 sg:pub.10.1007/s00280-010-1289-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021855880
272 https://doi.org/10.1007/s00280-010-1289-x
273 rdf:type schema:CreativeWork
274 sg:pub.10.1007/s00280-013-2224-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017758793
275 https://doi.org/10.1007/s00280-013-2224-8
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/81671 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044273521
278 https://doi.org/10.1038/81671
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/bjc.2011.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036295056
281 https://doi.org/10.1038/bjc.2011.13
282 rdf:type schema:CreativeWork
283 sg:pub.10.1038/modpathol.2008.96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023686924
284 https://doi.org/10.1038/modpathol.2008.96
285 rdf:type schema:CreativeWork
286 sg:pub.10.1038/ng0509-509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022216670
287 https://doi.org/10.1038/ng0509-509
288 rdf:type schema:CreativeWork
289 sg:pub.10.1038/nprot.2008.73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005355981
290 https://doi.org/10.1038/nprot.2008.73
291 rdf:type schema:CreativeWork
292 sg:pub.10.1038/sj.bjc.6604199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052387252
293 https://doi.org/10.1038/sj.bjc.6604199
294 rdf:type schema:CreativeWork
295 sg:pub.10.1038/sj.bjc.6605293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020189480
296 https://doi.org/10.1038/sj.bjc.6605293
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1002/gcc.20939 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006589958
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1016/0197-2456(89)90015-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053744925
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1021/jm2003552 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055952282
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1042/bse0400041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044072468
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1093/annonc/mdp270 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020236226
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1093/annonc/mdq784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034222572
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1096/fj.12-222893 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010089332
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1097/pas.0b013e31821e8761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044599683
315 rdf:type schema:CreativeWork
316 https://doi.org/10.1158/0008-5472.can-06-1986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012813855
317 rdf:type schema:CreativeWork
318 https://doi.org/10.1158/0008-5472.can-08-2216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048751420
319 rdf:type schema:CreativeWork
320 https://doi.org/10.1158/1078-0432.ccr-06-1715 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035724264
321 rdf:type schema:CreativeWork
322 https://doi.org/10.1158/1078-0432.ccr-06-3093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006258831
323 rdf:type schema:CreativeWork
324 https://doi.org/10.1158/1078-0432.ccr-08-0872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021371367
325 rdf:type schema:CreativeWork
326 https://doi.org/10.1158/1078-0432.ccr-11-1244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040372140
327 rdf:type schema:CreativeWork
328 https://doi.org/10.1158/1535-7163.mct-06-0761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034680444
329 rdf:type schema:CreativeWork
330 https://doi.org/10.1158/1535-7163.mct-09-0689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008255520
331 rdf:type schema:CreativeWork
332 https://doi.org/10.1200/jco.2006.08.6165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047140065
333 rdf:type schema:CreativeWork
334 https://doi.org/10.1200/jco.2007.12.4487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031178629
335 rdf:type schema:CreativeWork
336 https://doi.org/10.18632/oncotarget.1314 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020702285
337 rdf:type schema:CreativeWork
338 https://doi.org/10.4161/epi.3.6.7273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072302870
339 rdf:type schema:CreativeWork
340 https://doi.org/10.5772/27799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014327053
341 rdf:type schema:CreativeWork
342 https://www.grid.ac/institutes/grid.17089.37 schema:alternateName University of Alberta
343 schema:name Cross Cancer Institute, Edmonton, AB, Canada
344 rdf:type schema:Organization
345 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
346 schema:name BC Cancer Agency, Kelowna, BC, Canada
347 BC Cancer Agency, Vancouver, BC, Canada
348 rdf:type schema:Organization
349 https://www.grid.ac/institutes/grid.410356.5 schema:alternateName Queen's University
350 schema:name NCIC Clinical Trials Group, Kingston, ON, Canada
351 Queens University, Kingston, ON, Canada
352 rdf:type schema:Organization
353 https://www.grid.ac/institutes/grid.412541.7 schema:alternateName Vancouver General Hospital
354 schema:name Vancouver Prostate Centre, Vancouver, BC, Canada
355 rdf:type schema:Organization
356 https://www.grid.ac/institutes/grid.412745.1 schema:alternateName London Health Sciences Centre
357 schema:name London Health Sciences Centre, London, ON, Canada
358 rdf:type schema:Organization
359 https://www.grid.ac/institutes/grid.413292.f schema:alternateName Queen Elizabeth II Health Sciences Centre
360 schema:name QEII Health Sciences Centre, Halifax, NS, Canada
361 rdf:type schema:Organization
362 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
363 schema:name Princess Margaret Cancer Centre, Toronto, ON, Canada
364 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...